Evaxion Biotech A/S (EVAX) Competitors

$3.88
+0.01 (+0.26%)
(As of 03:29 PM ET)

EVAX vs. ZIVO, APTO, AIM, SNTI, PMCB, BCLI, TVGN, CRTX, COEP, and NKGN

Should you be buying Evaxion Biotech A/S stock or one of its competitors? The main competitors of Evaxion Biotech A/S include ZIVO Bioscience (ZIVO), Aptose Biosciences (APTO), AIM ImmunoTech (AIM), Senti Biosciences (SNTI), PharmaCyte Biotech (PMCB), Brainstorm Cell Therapeutics (BCLI), Tevogen Bio (TVGN), Cortexyme (CRTX), Coeptis Therapeutics (COEP), and NKGen Biotech (NKGN). These companies are all part of the "medical" sector.

Evaxion Biotech A/S vs.

Evaxion Biotech A/S (NASDAQ:EVAX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations, community ranking and profitability.

Evaxion Biotech A/S has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500.

ZIVO Bioscience has lower revenue, but higher earnings than Evaxion Biotech A/S. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion Biotech A/S$70K299.87-$22.12M-$6.76-0.57
ZIVO Bioscience$15.85K1,417.77-$7.78M-$3.80-2.10

Evaxion Biotech A/S has a net margin of 0.00% compared to ZIVO Bioscience's net margin of -11,068.75%. ZIVO Bioscience's return on equity of 0.00% beat Evaxion Biotech A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Evaxion Biotech A/SN/A -451.63% -149.27%
ZIVO Bioscience -11,068.75%N/A -630.91%

ZIVO Bioscience received 82 more outperform votes than Evaxion Biotech A/S when rated by MarketBeat users. Likewise, 61.11% of users gave ZIVO Bioscience an outperform vote while only 56.67% of users gave Evaxion Biotech A/S an outperform vote.

CompanyUnderperformOutperform
Evaxion Biotech A/SOutperform Votes
17
56.67%
Underperform Votes
13
43.33%
ZIVO BioscienceOutperform Votes
99
61.11%
Underperform Votes
63
38.89%

In the previous week, Evaxion Biotech A/S had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Evaxion Biotech A/S and 2 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 1.38 beat Evaxion Biotech A/S's score of 0.22 indicating that ZIVO Bioscience is being referred to more favorably in the news media.

Company Overall Sentiment
Evaxion Biotech A/S Neutral
ZIVO Bioscience Positive

11.0% of Evaxion Biotech A/S shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 41.6% of Evaxion Biotech A/S shares are held by company insiders. Comparatively, 13.4% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Evaxion Biotech A/S currently has a consensus target price of $11.00, indicating a potential upside of 183.51%. Given Evaxion Biotech A/S's higher probable upside, research analysts clearly believe Evaxion Biotech A/S is more favorable than ZIVO Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evaxion Biotech A/S
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
ZIVO Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

ZIVO Bioscience beats Evaxion Biotech A/S on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVAX vs. The Competition

MetricEvaxion Biotech A/SBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$20.99M$2.93B$5.11B$7.98B
Dividend YieldN/A2.20%36.92%3.93%
P/E Ratio-0.5726.45182.3318.77
Price / Sales299.87295.732,300.7977.71
Price / CashN/A162.0135.7331.18
Price / Book-3.325.635.454.47
Net Income-$22.12M-$45.68M$105.08M$217.09M
7 Day Performance2.92%4.59%1.73%1.93%
1 Month Performance-3.96%6.42%4.00%5.39%
1 Year Performance-76.05%10.58%8.31%11.87%

Evaxion Biotech A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZIVO
ZIVO Bioscience
0 of 5 stars
$7.50
-5.1%
N/A-56.6%$21M$30,000.00-1.638Earnings Report
Gap Down
APTO
Aptose Biosciences
2.0659 of 5 stars
$1.23
+1.7%
$19.80
+1,509.8%
-82.9%$19.34MN/A-0.1631Analyst Downgrade
News Coverage
AIM
AIM ImmunoTech
0 of 5 stars
$0.43
+2.4%
N/A-6.0%$21.57M$200,000.00-0.7126News Coverage
Gap Up
High Trading Volume
SNTI
Senti Biosciences
2.0044 of 5 stars
$0.40
+2.6%
$6.00
+1,393.3%
-61.0%$18.39M$2.56M-0.2548Earnings Report
PMCB
PharmaCyte Biotech
0 of 5 stars
$2.11
-1.9%
N/A-32.4%$17.83MN/A-1.762Positive News
BCLI
Brainstorm Cell Therapeutics
0.8195 of 5 stars
$0.37
-2.6%
N/A-82.5%$25.15MN/A-0.9029Earnings Report
Analyst Forecast
Short Interest ↑
News Coverage
Gap Down
TVGN
Tevogen Bio
0 of 5 stars
$0.99
+3.1%
N/AN/A$15.67MN/A0.0017Gap Down
CRTX
Cortexyme
0 of 5 stars
$0.92
-4.2%
N/A-40.9%$27.74MN/A-0.3155
COEP
Coeptis Therapeutics
2.7707 of 5 stars
$0.38
+5.6%
$3.00
+700.0%
-78.6%$12.99M$80,000.00-0.455Short Interest ↓
Positive News
NKGN
NKGen Biotech
0 of 5 stars
$1.29
-3.7%
N/AN/A$29.03M$80,000.000.00N/AGap Down

Related Companies and Tools

This page (NASDAQ:EVAX) was last updated on 5/16/2024 by MarketBeat.com Staff

From Our Partners